Olney R K, Murphy J, Forshew D, Garwood E, Miller B L, Langmore S, Kohn M A, Lomen-Hoerth C
ALS Treatment and Research Center, University of California, San Francisco, San Francisco, CA, USA.
Neurology. 2005 Dec 13;65(11):1774-7. doi: 10.1212/01.wnl.0000188759.87240.8b.
To determine whether patients with ALS-frontotemporal lobar dementia (FTLD) have a shorter survival and are less compliant with recommended treatments than those with ALS who have normal executive and behavioral function (classic ALS).
Survival analysis from ALS symptom onset to death included 81 of 100 consecutive patients who could be classified definitely as ALS with abnormal executive or behavioral function or as classic ALS. Criteria were defined for compliance with noninvasive positive-pressure ventilation (NPPV) and percutaneous endoscopic gastrostomy (PEG).
Median survival was 2 years 4 months for the 28 patients with FTLD and 3 years 3 months for the 53 patients with classic ALS (relative hazard for death 1.93, CI 1.09 to 3.43; p = 0.024). However, the relative hazard associated with FTLD (1.49) in the multivariate model was diminished by the association of FTLD with bulbar onset and older age and was not significant in this sample size. With bulbar onset, median survival was 2 years 0 months for the 14 with ALS-FTLD and 2 years 10 months for the 10 with classic ALS (relative hazard for death 2.78, CI 1.02 to 7.55; p = 0.045), and older age was not a significant risk. Noncompliance with NPPV and PEG were 75% and 72% in ALS-FTLD, respectively, vs 38% and 31% in classic ALS (relative risks 2.00 and 2.34; p = 0.013 and 0.022).
Survival is significantly shorter among patients with ALS-FTLD than with classic ALS. Furthermore, patients with ALS-FTLD are twice as likely to be noncompliant.
确定肌萎缩侧索硬化症合并额颞叶痴呆(FTLD)患者与执行和行为功能正常的肌萎缩侧索硬化症患者(经典型ALS)相比,生存期是否更短,对推荐治疗的依从性是否更低。
从肌萎缩侧索硬化症症状出现到死亡的生存分析纳入了100例连续患者中的81例,这些患者可明确分类为执行或行为功能异常的肌萎缩侧索硬化症患者或经典型肌萎缩侧索硬化症患者。定义了无创正压通气(NPPV)和经皮内镜下胃造口术(PEG)的依从性标准。
28例FTLD患者的中位生存期为2年4个月,53例经典型ALS患者的中位生存期为3年3个月(死亡相对风险为1.93,可信区间为1.09至3.43;p = 0.024)。然而,在多变量模型中,与FTLD相关的相对风险(1.49)因FTLD与延髓起病和年龄较大相关而降低,在该样本量中不显著。对于延髓起病的患者,14例ALS-FTLD患者的中位生存期为2年0个月,10例经典型ALS患者的中位生存期为2年10个月(死亡相对风险为2.78,可信区间为1.02至7.55;p = 0.045),年龄较大不是显著风险。ALS-FTLD患者对NPPV和PEG的不依从率分别为75%和72%,而经典型ALS患者分别为38%和31%(相对风险分别为2.00和2.34;p = 0.013和0.022)。
ALS-FTLD患者的生存期明显短于经典型ALS患者。此外,ALS-FTLD患者不依从的可能性是经典型ALS患者的两倍。